Aberrantly expressed transcription factors C/EBP and SOX4 have positive effects in the development of chronic myeloid leukemia

Dong,Fei; Zhang,Guili; Zhang,Xia; Liu,Xuena; Wang,Na; Sun,Chengming

doi:10.3892/mmr.2017.7486

Aberrantly expressed transcription factors C/EBP and SOX4 have positive effects in the development of chronic myeloid leukemia

Authors:
- Fei Dong
- Guili Zhang
- Xia Zhang
- Xuena Liu
- Na Wang
- Chengming Sun
View Affiliations

Affiliations: School of Medicine, Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Laboratory Center, Yantai Yuhuangding Hospital Affiliated to Qingdao University Medical College, Yantai, Shandong 264000, P.R. China
Published online on: September 13, 2017 https://doi.org/10.3892/mmr.2017.7486
Pages: 7131-7137

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the expression and significance of CCAAT/enhancer binding protein α (C/EBPα) and SRY‑related high mobility group box containing transcription factor 4 (SOX4) in chronic myeloid leukemia (CML). Bone marrow samples were collected from patients with CML, and peripheral blood mononuclear cells were collected from healthy controls. Protein and mRNA were extracted from the collected samples, and analyzed using western blotting and reverse transcription‑quantitative polymerase chain reaction analyses, respectively. Spearman's method was used to evaluate the correlation between the expression levels of these two genes, with P<0.05 considered to indicate a statistically significant difference. A total of 79 patients, including 57 patients with newly diagnosed CML and 22 patients treated with imatinib therapy, and 30 controls were enrolled. The expression of SOX4 was upregulated in the patients with CML, whereas the expression of C/EBPα was downregulated (P<0.05). However, no differences were observed among the chronic, accelerated and blastic CML phases, respectively (P>0.05). In addition, no associations were found between the changes in expression and age, gender, white blood cells or the expression of breakpoint cluster region/abelson in patients (P>0.05). However, the expression of SOX4 was negatively correlated with the expression of C/EBPα (P<0.01). Following imatinib treatment, the expression of SOX4 was downregulated in the progression‑free patients, but upregulated in the blastic phase patients, whereas the expression of C/EBPα showed the opposite trend. Therefore, C/EBPα and SOX4 were important and negatively associated with the process of CML, and the C/EBPα‑SOX4 axis may be a novel potential therapeutic target for the treatment of CML.

View Figures

View References

1	Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI
2	Sawyers CL: Chronic myeloid leukemia. N Engl J Med. 340:1330–1340. 1999. View Article : Google Scholar : PubMed/NCBI
3	Pavlu J, Szydlo RM, Goldman JM and Apperley JF: Three decades of transplantation for chronic myeloid leukemia: What have we learned? Blood. 117:755–763. 2011. View Article : Google Scholar : PubMed/NCBI
4	Howlader N, Noone AM, Krapcho M, Newman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute; Bethesda, MD: Based on November 2011 SEER data submission, posted to the SEER web site. April. 2012, https://seer.cancer.gov/archive/csr/1975_2009_pops09/
5	Parker WT, Ho M, Scott HS, Hughes TP and Branford S: Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 119:2234–2238. 2012. View Article : Google Scholar : PubMed/NCBI
6	Apperley JF: Chronic myeloid leukaemia. Lancet. 385:1447–1459. 2015. View Article : Google Scholar : PubMed/NCBI
7	Friedman AD: C/EBPα in normal and malignant myelopoiesis. Int J Hematol. 101:330–341. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zeisig BB, Kulasekararaj AG, Mufti GJ and So CW: SnapShot: Acute myeloid leukemia. Cancer Cell. 22:698.e12012. View Article : Google Scholar
9	Bhattaram P, Penzo-Méndez A, Sock E, Colmenares C, Kaneko KJ, Vassilev A, Depamphilis ML, Wegner M and Lefebvre V: Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat Commun. 1:92010. View Article : Google Scholar : PubMed/NCBI
10	Song G, Wang L, Bi K and Jiang G: Regulation of the C/EBPα signaling pathway in acute myeloid leukemia (Review). Oncol Rep. 33:2099–2106. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J, Levantini E, et al: Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell. 24:575–588. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kuwahara M, Yamashita M, Shinoda K, Tofukuji S, Onodera A, Shinnakasu R, Motohashi S, Hosokawa H, Tumes D, Iwamura C, et al: The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses TH2 differentiation. Nat Immunol. 13:778–786. 2012. View Article : Google Scholar : PubMed/NCBI
13	Aue G, Du Y, Cleveland SM, Smith SB, Davé UP, Liu D, Weniger MA, Metais JY, Jenkins NA, Copeland NG and Dunbar CE: Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood. 118:4674–4681. 2011. View Article : Google Scholar : PubMed/NCBI
14	Sandoval S, Kraus C, Cho EC, Cho M, Bies J, Manara E, Accordi B, Landaw EM, Wolff L, Pigazzi M and Sakamoto KM: Sox4 cooperates with CREB in myeloid transformation. Blood. 120:155–165. 2012. View Article : Google Scholar : PubMed/NCBI
15	Vervoort S, van Boxtel R and Coffer PJ: The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: Friend or foe? Oncogene. 32:3397–3409. 2013. View Article : Google Scholar : PubMed/NCBI
16	Jafarnejad SM, Ardekani GS, Ghaffari M and Li G: Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci. 70:2677–2696. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, et al: SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 121:148–155. 2013. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Suknuntha K, Ishii Y, Tao L, Hu K, McIntosh BE, Yang D, Swanson S, Stewart R, Wang JY, Thomson J and Slukvin I: Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res. 15:678–693. 2015. View Article : Google Scholar : PubMed/NCBI
20	Bauer S, Buchanan S and Ryan I: Tyrosine kinase inhibitors for the treatment of chronic-phase chronic myeloid leukemia: Long-term patient care and management. J Adv Pract Oncol. 7:42–54. 2016.PubMed/NCBI
21	Porse BT, Bryder D, Theilgaard-Mönch K, Hasemann MS, Anderson K, Damgaard I, Jacobsen SE and Nerlov C: Loss of C/EBPα cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med. 202:85–96. 2005. View Article : Google Scholar : PubMed/NCBI
22	Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, et al: Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 21:853–863. 2004. View Article : Google Scholar : PubMed/NCBI
23	Baer C, Claus R, Frenzel LP, Zucknick M, Park YJ, Gu L, Weichenhan D, Fischer M, Pallasch CP, Herpel E, et al: Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res. 72:3775–3785. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chim C, Wong AS and Kwong YL: Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol. 119:988–990. 2002. View Article : Google Scholar : PubMed/NCBI
25	Annamaneni S, Kagita S, Gorre M, Digumarti RR, Satti V and Battini MR: Methylation status of CEBPA gene promoter in chronic myeloid leukemia. Hematology. 19:42–44. 2014. View Article : Google Scholar : PubMed/NCBI
26	Thiel AT, Feng Z, Pant DK, Chodosh LA and Hua X: The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia. Haematologica. 98:918–927. 2013. View Article : Google Scholar : PubMed/NCBI
27	Dedhia PH, Keeshan K, Uljon S, Xu L, Vega ME, Shestova O, Zaks-Zilberman M, Romany C, Blacklow SC and Pear WS: Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia. Blood. 116:1321–1328. 2010. View Article : Google Scholar : PubMed/NCBI
28	Fung TK, Leung AY and So CW: Sox4you: A new player in C/EBPα leukemia. Cancer cell. 24:557–559. 2013. View Article : Google Scholar : PubMed/NCBI
29	Aue G, Du Y, Cleveland SM, Smith SB, Davé UP, Liu D, Weniger MA, Metais JY, Jenkins NA, Copeland NG and Dunbar CE: Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood. 118:4674–4681. 2011. View Article : Google Scholar : PubMed/NCBI
30	Du Y, Spence SE, Jenkins NA and Copeland NG: Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood. 106:2498–2505. 2005. View Article : Google Scholar : PubMed/NCBI
31	Hanfstein B, Shlyaknto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, et al: Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 28:1988–1992. 2014. View Article : Google Scholar : PubMed/NCBI